Limited Product Line Will Become Vulnerability For Honz Pharma
This article was originally published in PharmAsia News
Executive Summary
Although pediatric drug manufacturer Honz Pharma's leading product, Rui Zhiqing (nimesulide particles), commands significant market share, investment advisor Guo Fanli points out that heavy reliance on this single product will eventually become a disadvantage